Western pharma firms sign $73.6B deals with Chinese groups, pipeline to exceed $250B by 2026

Western pharmaceutical companies are accelerating licensing and partnership deals with Chinese biotech firms, with announced agreements totaling $73.6 billion and projected to surpass $250 billion by 2026. This marks a strategic pivot toward China as a source of innovative drug candidates, reflecting a shift in global R&D flows. The trend underscores China's rising role in pharma innovation, though regulatory and geopolitical risks remain.